- Voyageur (VM) has closed the first tranche of its C$650,000 non-brokered private placement offering
- Under the first closing, the company issued 2,571,369 units for aggregate gross proceeds of $179,995.93
- It expects to complete one or more tranches in January 2023
- Voyageur is focused on the development of barium and iodine APIs, as well as imaging contrast agents for the medical imaging marketplace
- Voyageur Pharmaceuticals (VM) is down by 5.56 per cent trading at $0.085 per share
Voyageur (VM) has closed the first tranche of its C$650,000 non-brokered private placement offering.
Under the first closing, the company issued 2,571,369 units for aggregate gross proceeds of $179,995.93.
Each unit is being offered at a price of $0.07 and is comprised of one common share and one common share purchase warrant.
Each warrant entitles the holder to purchase one common share for $0.12 for two years from the date of issuance.
Voyageur expects to complete one or more tranches in January 2023.
It will allocate the proceeds in the following order:
| Commissions and offering costs | $35,000 |
| SmoothX and corporate marketing | $175,000 |
| FDA EMA testing | $180,000 |
| Legal | $50,000 |
| Auditing fees | $60,000 |
| Corporate G&A | $150,000 |
| Total | $650,000 |
Voyageur is focused on developing barium and iodine APIs, as well as imaging contrast agents for the medical imaging marketplace.
Voyageur Pharmaceuticals (VM) is down by 5.56 per cent trading at $0.085 per share as of 10:24 am ET.
